Evidence map›Paper›PMID 34868926›Full record

ArticleFrontiers in oncology2021

Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review.

Min Deng, Huirong Chai, Meng Yang, Xueman Wei, Wenjun Zhang, Xuebin Wang, Juanjuan Li, Zhuo Wang, Haitao Chen

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Min DengCollege of life sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.
Huirong ChaiDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Meng YangDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Xueman WeiDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Wenjun ZhangDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Xuebin WangDepartment of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Juanjuan LiDepartment of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhuo WangCollege of life sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.
Haitao ChenDepartment of Geriatrics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Changhai Hospital · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.

methodsWe present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.

resultsSJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.

conclusionMost cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment.

Indexed as

cutaneous adverse eventsdrug eruptionenzalutamideprostate cancerStevens-Johnson syndrome

Identifiers

PMID34868926
PMCPMC8635634
OpenAlexW3212251879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.